Daewoong registers patient for Phase 3 trial of Coviblock
By Nho, Byung Chul | translator Alice Kang
21.06.16 06:20:00
가나다라
0
The only domestic drug attempting to demonstrate infection prevention effect after exposure to COVID-19 virus
Development in progress after completion of its phase 2b trial… aims to receive conditional approval within Q3
▲Clinical trial approval status of Daewoong Pharmaceutical’s COVID-19 treatment Coviblock as registered on the Pharmaceutical Integrated intelligence system (image: screen capture of the Pharmaceutical Integrated intelligence system webpage)
The first patient for the Phase III trial of Daewoong Pharmaceutical's COVID-19 treatment candidate 'DWJ1248 (brand name: Coviblock)’ has been registered.According to the clinical trial approval status disclosed on the Pharmaceutical Integrated intelligence system webpage, Daewoong Pharmaceuticals had registered its first patient on the 7th this month for its double-blind, randomized, controlled Phase III clinical trial for Coviblock to assess its effectiveness in preventing infections after exposure to the COVID-19 virus.
The clinical trial will investigate the efficacy of Coviblock in preventing infections in people in self-isolation due to exposure to the COVID-19 virus. This is the
Nho, Byung Chul(sasiman@dailypharm.com)
If you want to see the full article, please JOIN US (click)